Product Profile PDF Download

Author:
Publisher:
ISBN:
Category : United States
Languages : en
Pages : 70

View

Book Description

Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240076662
Category : Medical
Languages : en
Pages : 30

View

Book Description
HIV-1 drug resistance tests may be useful tools for optimizing ART regimens when used in the context of information about viral load, immune and clinical status, adherence practices and available treatment options. Several types of drug resistance tests are available, either as commercial kits or based on published methods for in-house assays. The target product profile for HIV drug resistance tests in low- and middle-income countries: Africa is designed to guide the development of new HIV drug resistance tests in the era of dolutegravir-based antiretroviral therapy (ART) and to facilitate the evaluation of the suitability of currently available HIV drug resistance tests for specific applications. The target product profiles focus on the new-term future for available ART regimens and their use and anticipates an innovate test that will meet the projected demand.

Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240067175
Category : Medical
Languages : en
Pages : 26

View

Book Description

Author:
Publisher: World Health Organization
ISBN: 9240003835
Category : Medical
Languages : en
Pages : 8

View

Book Description

Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240081259
Category : Medical
Languages : en
Pages : 20

View

Book Description
Preterm birth (i.e. birth before 37 completed weeks of gestation) is the leading cause of neonatal mortality globally. Preterm newborns that survive are at an increased risk of a number of short- and long-term adverse health outcomes, including chronic lung disease, infections and neurological, visual and auditory disabilities. A number of tocolytic agents are currently in use internationally to slow down or stop the progression of labour. However, none of those has shown substantive improvements in fetal or newborn health outcomes.There is an urgent need for new agents to manage preterm birth, thereby reducing adverse outcomes for newborns. An initial target product profile (TPP) for drugs to manage preterm labour was developed and published by external parties. Following the identification of an unmet public health need, WHO has considered the already published TPP as the basis for developing a WHO TPP. The purpose of this TPP is to guide product developers and funders on the key characteristics and desired attributes of therapeutic agents for pregnant women experiencing spontaneous preterm labour.

Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240081135
Category : Medical
Languages : en
Pages : 20

View

Book Description
TPP for drugs to prevent pre-eclampsia Pre-eclampsia and eclampsia affect 4.6% and 1.4% of pregnant women, respectively. They account for the majority of maternal deaths and stillbirths due to hypertensive disorders of pregnancy. Pre-eclampsia can also negatively affect fetal growth, and increase the risk of preterm birth and fetal death. There is an urgent need to identify new agents to prevent pre-eclampsia. An initial target product profile (TPP) for drugs to prevent pre-eclampsia was developed and published by external parties. Following the identification of an unmet public health need, WHO has considered the already published TPP as the basis for developing a WHO TPP. This WHO TPP describes the key characteristics and desired attributes of preventive agents that should be administered to pregnant women identified as being at increased risk of developing pre-eclampsia, accompanied by monitoring for the development of pre-eclampsia. This TPP outlines minimal and preferred characteristics of a medicine that should: - prevent the development of pre- eclampsia; - have a good safety profile during pregnancy; - be commenced early in pregnancy (before 20 weeks’ gestation) and continued throughout pregnancy and postpartum as required; - be suitable for administration in any health care setting where pregnant women receive antenatal care, including in LMICs.

Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240081151
Category : Medical
Languages : en
Pages : 24

View

Book Description

Author:
Publisher: World Health Organization
ISBN: 9240003819
Category : Medical
Languages : en
Pages : 8

View

Book Description

Author: Ephrem Habyarimana
Publisher: Springer Nature
ISBN: 9819743478
Category :
Languages : en
Pages : 457

View

Book Description

Author: World Health Organization
Publisher: World Health Organization
ISBN: 9240081232
Category : Medical
Languages : en
Pages : 20

View

Book Description
Preterm birth (i.e. birth before 37 completed weeks of gestation) is the leading cause of neonatal mortality globally. There is an urgent need for new agents to prevent preterm birth, thereby reducing adverse outcomes for newborns. An initial target product profile (TPP) for drugs to prevent spontaneous preterm birth was developed and published by external parties. Following the identification of an unmet public health need, WHO has considered the already published TPP as the basis for developing a WHO TPP. The purpose of this TPP is to guide product developers and funders on the key characteristics and desired attributes of preventive agents that should be administered to pregnant women at increased risk of spontaneous preterm birth. This TPP outlines the minimal and preferred characteristics of a medicine that should: - reduce the likelihood of preterm birth and thus prevent (or mitigate) adverse newborn outcomes due to prematurity; - have an excellent safety profile during pregnancy; - be suitable for prescription or administration by skilled health personnel in any health care setting where pregnant women receive antenatal care, including in LMICs; - be commenced early in pregnancy and can be continued throughout pregnancy, as required.